Understanding The Role Of Neurotransmitters In The Treatment Of Depression
Major depressive disorder (MDD) is common, affecting an estimated 16 million US adults each year. However, less than 40% of patients receive minimally adequate treatment. In this webinar, Robin Nelson MD, psychiatrist at DGR Behavioral Health LLC in Wyomissing, PA, and Prakash Masand, MD, Chairman and CEO of Global Medical Education, New York, NY, highlight the unmet needs in the treatment of MDD and review the monoamine hypothesis in the etiology of MDD and the monoamine circuits within the brain. …
Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). Specific PsychU programs may be supported by OPDC, OAPI and other committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsor or the sponsors of the specific PsychU program in which such opinions are expressed. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC and OAPI.